BOTOX és

Phase 3Small molecule

UUniversity Hospital, Clermont-Ferrand

BOTOX és is one of 37 small molecule programs targeting Essential Tremor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential TremorActive, not recruiting

Essential TremorPhase 3

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Essential Tremor

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

1 2

Epidiolex

Jazz Pharmaceuticals

Approved

—3

Marinol

Alnylam Pharmaceuticals

Approved

—4

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Topamax

Mirapex

1 7

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Xyrem

1 9

Zonegran

AAzurity Pharmaceuticals

Phase 2

2 10

Fycompa

CCatalyst Biosciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Essential Tremor1 trial

Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor

Completed·UUniversity Hospital, Clermont-Ferrand·Phase 3·NCT02555982·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BOTOX és. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BOTOX és compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BOTOX és. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Clermont-Ferrand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Clermont-Ferrand

BOTOX és

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Essential Tremor1 trial

References

Drug Info

Quick Facts

Related News